Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and good tolerability for up to 3 years in patients with ...
Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion ...
LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...
We recently compiled a list of the 11 Best Kid-Friendly Stocks to Invest In. Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list. On March 3, TheFly reported that Kyowa Kirin ...
BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 ...
Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results